Statins prescribing pattern in the UK

  • Pharmacoepidemiol Drug Saf

  • from Sarfaroj Khan
  • Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The availability of generic simvastatin and atorvastatin has significantly reduced overall expenditure on statins in England.
  • When costs are similar, potency appears to influence prescribing choice.

Why this matters

  • Expenditure on statins has been a significant contributor to the increasing burden on the National Health Service budget.

Key results

  • During the period 1998 to 2004, driven by branded simvastatin and atorvastatin, a 125% increase in the primary care expenditure on statins was recorded (from £170,388,500 to £738,114,800).
  • The average strengths of prescribed generic simvastatin and atorvastatin were significantly higher than branded simvastatin (P<.005 and atorvastatin respectively.>
  • In terms of use, branded atorvastatin exceeded branded simvastatin before 2003.
  • After patent expiry of branded simvastatin in 2003, generic simvastatin achieved 66% of the statins market share by 2011.
  • Similarly, after the patent expiry of branded atorvastatin in 2012, generic atorvastatin had 50% of the market share in primary care by 2015.
  • Rosuvastatin failed to make a significant effect on the English market.

Study design

  • Retrospective study evaluated the changes in primary care use pattern of all statins in England between 1998 and 2015.
  • Funding: None disclosed.

Limitations

  • Data derived from prescriptions dispensed rather than prescription written.